Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate

• Main Authors: Nadarajan, V.S., Phan, C.L., Ang, C.H., Liang, K.L., Gan, G.G., Bee, P.C., Zakaria, Z.
• Format: Article
• Published: Springer Verlag (Germany) 2011
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/12024/; http://link.springer.com/article/10.1007%2Fs12185-011-0796-9; http://dx.doi.org/10.1007/s12185-011-0796-9

The outcome of treating chronic myeloid leukemia (CML) with imatinib mesylate (IM) is inferior when therapy is commenced in late chronic or accelerated phase as compared to early chronic phase. This may be attributed to additional genomic alterations that accumulate during disease progression. We so...